These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 18037293)

  • 1. Vitamin D supplementation and response to aromatase inhibitors in postmenopausal women with hormone-receptor positive breast cancer.
    Dizdar O; Bulut N; Altundag K
    Breast; 2008 Apr; 17(2):120. PubMed ID: 18037293
    [No Abstract]   [Full Text] [Related]  

  • 2. Vitamin D intake may be a predictor of response to aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
    Dizdar O; Bulut N; Altundag K
    Breast Cancer Res Treat; 2008 May; 109(2):403. PubMed ID: 17624607
    [No Abstract]   [Full Text] [Related]  

  • 3. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
    Coleman RE; Body JJ; Gralow JR; Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase inhibitors and bone health.
    Bundred NJ
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aromatase inhibitors for metastasing breast cancer in postmenopausal women. A survey of a Cochrane review].
    Aziz M; Skougaard K; Kamby C; Nielsen DL
    Ugeskr Laeger; 2008 Jun; 170(25):2248-52. PubMed ID: 18565316
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of osteoporosis after breast cancer.
    Reid DM
    Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitors in breast cancer.
    Hiscox S; Davies EL; Barrett-Lee P
    Maturitas; 2009 Aug; 63(4):275-9. PubMed ID: 19577386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
    Barginear M; Clotfelter A; Poznak CV
    Clin Breast Cancer; 2009 May; 9(2):72-6. PubMed ID: 19433386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
    Seo JH; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):261-6. PubMed ID: 18365197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
    Clunie GP; Clark A; Mortimer CJ; Stephenson S; Aitken J; Smith C; Sherwin E; Archer TJ
    Eur J Surg Oncol; 2009 May; 35(5):475-80. PubMed ID: 18950981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer in men: should aromatase inhibitors become first-line hormonal treatment?
    Nordman IC; Dalley DN
    Breast J; 2008; 14(6):562-9. PubMed ID: 19000052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparanase activity and bone loss in postmenopausal breast cancer patients.
    Altundag K; Altundag O; Baptista MZ; Akyurek S
    J Clin Oncol; 2005 Dec; 23(34):8916-7; author reply 8917-8. PubMed ID: 16314656
    [No Abstract]   [Full Text] [Related]  

  • 17. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
    Mousa NA; Crystal P; Wolfman WL; Bedaiwy MA; Casper RF
    Menopause; 2008; 15(5):875-84. PubMed ID: 18480735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition of postmenopausal status, age of the breast cancer patients and the outcome of aromatase inhibitors treatment.
    Aksoy S; Dizdar O; Altundag K
    Breast; 2008 Oct; 17(5):433-5. PubMed ID: 18565752
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in adjuvant endocrine therapy for postmenopausal women.
    Lin NU; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.